Investigational drug · Phase 3
Olatorepatide
Also called: HS-20094
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
6 still active
All registered trials
4
Any phase or sponsor naming "Olatorepatide"
First trial start
2024
Feb 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olatorepatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
- Overweight or Obesity
- Overweight or Obesity Without Diabetes
- Hidradenitis Suppurativa
- Overweight
- Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Hidradenitis suppurativa · Cardiovascular and metabolic · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Olatorepatide" as an intervention, largest first.
- Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without DiabetesPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07896265 · 3,000 participants (planned) · Start Nov 18, 2026 · Primary completion Dec 19, 2028
Drug: Olatorepatide; Placebo · For: Overweight or Obesity Without Diabetes
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07685808 · 360 participants (planned) · Start Jul 28, 2026 · Primary completion Jan 21, 2028
Drug: Olatorepatide; Placebo · For: Overweight or Obesity
Sites: Mobile, Alabama; Walnut Creek, California; Waterbury, Connecticut · 22 sites in all
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07830329 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 24, 2028
Drug: Olatorepatide; Placebo · For: Hidradenitis Suppurativa
Sites: The Bronx, New York
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07431086 · 120 participants · Start Mar 16, 2026 · Primary completion Nov 13, 2026
Drug: Olatorepatide; Placebo · For: Overweight or Obesity
Sites: Walnut Creek, California; Winter Park, Florida; San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- HDM1005Phase 35 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Obstructive Sleep Apnea (OSA) and Obesity, Obesity, Type 2 Diabetes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.